Journal List > Korean J Radiol > v.18(4) > 1027362

Lee, Jeong, Lee, Lee, Lee, Kim, Choi, and Choo: Predictive Value of Cardiac Magnetic Resonance Imaging-Derived Myocardial Strain for Poor Outcomes in Patients with Acute Myocarditis

Abstract

Objective

To evaluate the utility of cardiovascular magnetic resonance (CMR)-derived myocardial strain measurement for the prediction of poor outcomes in patients with acute myocarditis.

Materials and Methods

We retrospectively analyzed data from 37 patients with acute myocarditis who underwent CMR. Left ventricular (LV) size, LV mass index, ejection fraction and presence of myocardial late gadolinium enhancement (LGE) were analyzed. LV circumferential strain (EccSAX), radial strain (ErrSAX) from mid-ventricular level short-axis cine views and LV longitudinal strain (EllLV), radial strain (ErrLax) measurements from 2-chamber long-axis views were obtained. In total, 31 of 37 patients (83.8%) underwent follow-up echocardiography. The primary outcome was major adverse cardiovascular event (MACE). Incomplete LV functional recovery was a secondary outcome.

Results

During an average follow-up of 41 months, 11 of 37 patients (29.7%) experienced MACE. Multivariable Cox proportional hazard regression analysis, which included LV mass index, LV ejection fraction, the presence of LGE, EccSAX, ErrSAX, EllLV, and ErrLax values, indicated that the presence of LGE (hazard ratio, 42.88; p = 0.014), together with ErrLax (hazard ratio, 0.77 per 1%, p = 0.004), was a significant predictor of MACE. Kaplan-Meier analysis demonstrated worse outcomes in patient with LGE and an ErrLax value ≤ 9.48%. Multivariable backward regression analysis revealed that ErrLax values were the only significant predictors of LV functional recovery (hazard ratio, 0.54 per 1%; p = 0.042).

Conclusion

CMR-derived ErrLax values can predict poor outcomes, both MACE and incomplete LV functional recovery, in patients with acute myocarditis, while LGE is only a predictor of MACE.

INTRODUCTION

Myocarditis is an acute or chronic inflammatory disease of the myocardium that can be caused by infectious pathogens such as viruses, bacteria, toxic fungi and Chlamydia, as well as by toxic and hyper-sensitivity reactions (1). The short-term prognosis for acute myocarditis is typically good, but dilated cardiomyopathy or sudden cardiac death can also occur (123). Several parameters, including clinical symptoms such as advanced New York Heart Association (NYHA) functional classes, certain viruses or immunohistologic signs of inflammation identified by endomyocardial biopsy (EMB), left ventricle (LV) function, and late gadolinium enhancement (LGE), are predictors of poor outcomes (456). Because EMB is invasive, has a complication rate of 6% and is not appropriate for all patients (7), cardiovascular magnetic resonance (CMR) can be an alternative tool for the prediction of poor outcomes. CMR is non-invasive and can assess LV size, function and LGE simultaneously.
Left ventricular myocardial systolic strain and deformation parameters are altered during early-stage pathogenesis, and can be measured with CMR (8910). Tagged-CMR, in which magnetization saturation bands arranged in a grid format are placed onto the myocardium, is an established method for the assessment of regional LV function. However, myocardial tagging has not been widely adopted due to the necessity for additional scans and complex, time-consuming post-processing of images (1112). Recently developed feature tracking software enables the measurement of myocardial strain using CMR cine images. The software tracks endocardial and epicardial borders across frames to quantify the LV wall motion during the cardiac cycle. CMR-derived feature tracking methods are vendor-independent and thus do not require additional sequences (13). Furthermore, feature tracking-derived measurements of circumference have acceptable inter-observer reproducibility, and feature tracking-derived myocardial strain can predict acute myocarditis with high sensitivity and specificity (914). However, there have been no reports on the prognostic value of CMR-derived myocardial strain measurements in acute myocarditis patients.
Therefore, the primary objective of this study was to evaluate the utility of CMR-derived myocardial strain measurements for the prediction of poor outcomes, defined as major adverse cardiac events (MACE) or incomplete LV functional recovery, in patients with acute myocarditis.

MATERIALS AND METHODS

Study Population

This retrospective study was approved by the Institutional Review Board of our hospitals. This study reviewed the database of 42 patients with suspected myocarditis who underwent CMR between August 2004 and March 2014 in Pusan National University Hospital or Pusan National University Yangsan Hospital. Based on previous descriptions of myocarditis (101516171819), acute myocarditis patients were included who presented with the following: 1) symptoms and signs suggestive of acute myocarditis, such as fever, viral prodrome, chest pain, dyspnea, palpitation, effort intolerance or presyncope, or syncope within 6 weeks of admission; 2) evidence of structural or functional abnormalities on echocardiography or CMR, or of myocardial injury indicated by elevated biomarkers (troponin I level > 0.1 ng/mL or creatine kinase MB [CK-MB] fraction > 6.2 ng/mL); and 3) no evidence of coronary artery disease observed on coronary angiography in patients older than 35 years. Patients with coronary artery disease (n = 3), chronic myocarditis (n = 1), and a patient who did not undergo coronary angiography (n = 1) were excluded. A total of 37 patients comprised the study population. Medical records were reviewed for clinical symptoms, demographic factors (age, sex, weight, and height), past history (hypertension, hypercholesterolemia, diabetes, smoking), electrocardiogram (ECG) findings, initial troponin I, brain natriuretic peptide and CK-MB levels, pathologic EMB results, CMR findings and beta-blocker medication status. Control study subjects were 10 normal individuals (mean age, 36.2 ± 10 years; 5 females) with no history of cardiovascular disease, unremarkable findings on physical examination, and a low probability of heart disease.

Cardiovascular Magnetic Resonance

Cardiovascular magnetic resonance was performed using 1.5T (Magnetom Sonata, Siemens Healthcare, Berlin, Germany [12 patients]; Magnetom Avanto, Siemens Healthcare, Erlangen, Germany [16 patients]), and 3T (Achieva, Philips Healthcare, Best, the Netherlands [7 patients and 10 normal subjects]; Magnetom Skyra, Siemens Healthcare, Erlangen, Germany [2 patients]) CMR imaging scanners. All cine images were acquired using a balanced, steady-state, free precession sequence during a gentle expiratory breath-hold. Short-axis cine images from cardiac base to apex, and long-axis cine images in 2- and 4-chamber views were obtained using the following scan parameters: echo time (TE)/repetition time (TR)/flip-angle = 1.1 ms/54.8 ms/50°, slice thickness = 8 mm, gap = 2 mm, matrix = 192 × 119 (Magnetom Sonata); TE/TR/flip-angle = 1.2 ms/60.1 ms/79°, slice thickness = 8 mm, gap = 2 mm, matrix = 192 × 109 (Magnetom Avanto); TE/TR/flip-angle = 1.5 ms/2.9 ms/40°, slice thickness = 10 mm, no gap, matrix = 176 × 168 (Achieva); TE/TR/flip-angle = 1.1 ms/57.9 ms/79°, slice thickness = 8 mm, gap = 2 mm, matrix = 192 × 109 (Magnetom Skyra). LGE imaging was performed with whole-heart coverage of the short-axis following administration of 0.2 mmol/kg gadobutrol (Gadovist, Bayer Healthcare, Leverkusen, Germany), using a T1-weighted mid-diastolic inversion recovery sequence and a patient-adapted prepulse delay (TE/TR/flip-angle = 4.3 ms/750 ms/30°, slice thickness = 8 mm, gap = 2 mm, matrix = 256 × 148 [Magnetom Sonata]; TE/TR/flip-angle = 5.6 ms/488 ms/25°, slice thickness = 8 mm, gap = 2 mm, matrix = 256 × 134 [Magnetom Avanto]; TE/TR/flip-angle = 3 ms/6.1 ms/25°, slice thickness 10 mm, no gap, matrix = 224 × 166 [Achieva]; TE/TR/flip-angle = 3.2 ms/751 ms/25°, slice thickness = 8 mm, gap = 2 mm, matrix = 256 × 156 [Magnetom Skyra]). Images were analyzed by a blinded radiologist with 7 years' experience with cardiac imaging. All routine CMR analyses, except strain and strain rate, were performed using commercially available software (IntelliSpace Portal, Philips Healthcare, Cleveland, OH, USA). LV end-diastolic volume index (LVEDVI), LV end-systolic volume index (LVESVI), LV myocardial mass index (LVMI), LV ejection fraction (EF) and right ventricle EF (RVEF) were derived from short axis-segmentation of CMR. All strain parameters were measured using dedicated software (CVI42, Circle Cardiovascular Imaging Inc., Calgary, Canada) (Fig. 1). LV circumferential strain (EccSAX) and radial strain (ErrSAX) measurements were obtained using mid-ventricular level short-axis cine views. LV longitudinal strain (EllLV) and radial strain (ErrLax) measurements were obtained from a 2-chamber long-axis view. All strain values were calculated by averaging the peak segmental values of radial, circumferential, and longitudinal strain for each strain direction. To assess intra-observer agreement, all measurements were repeated after 1 month in 20 randomly selected subjects. To assess inter-observer agreement for myocardial strain, all myocardial strains were measured in those subjects by another radiologist with 5 years' experience with cardiac imaging. Patterns and presence of myocardial LGE were assessed visually. Patterns of LGE were classified as subendocardial, subepicardial, mid-wall or transmural enhancement.
We performed a subgroup analysis between myocarditis patients with a preserved LVEF (≥ 55%, n = 16), myocarditis patients with impaired LVEF (< 55%, n = 21), and normal subjects (n = 10).

Clinical Outcomes

Outcomes were assessed by chart review or telephone interview. As a primary outcome, all patients were followed up to assess the incidence rate of MACE, defined in terms of cardiac death, heart transplantation, implanted cardioverter defibrillator or pacemaker, rehospitalization following a cardiac event, or embolic stroke. Time to MACE is provided in days. Incomplete LV functional recovery was a secondary outcome in the patient group (n = 31) who underwent follow-up echocardiography after 1 year. Incomplete LV functional recovery was defined as an LVEF value < 60% (5). Two-dimensional transthoracic echocardiography was performed by a diagnostic cardiac sonographer using commercial echocardiographic systems (iE33, Philips Electronics, Amsterdam, the Netherlands; Vivid-Q, GE Medical Systems Israel Ltd., Tirat Carmel, Israel; Sequoia, Siemens AG, Munich, Germany) according to a standardized protocol in the cardiac laboratories of Pusan National University Hospital and Pusan National University Yangsan Hospital. The LVEF was measured using the modified Simpson's method as recommended by the American Society of Echocardiography (20).

Statistical Analysis

Statistical analysis was performed using the SPSS for Windows (SPSS Inc., Chicago, IL, USA) and MedCalc (ver. 14.10.2, MedCalc Software, Mariakerke, Belgium) software packages. Categorical group data, presented as percentages, were compared using the chi-square test or Fisher's exact test as appropriate. Continuous variables are presented as means ± SDs and were compared using the Student's t test for normally distributed data or the Mann-Whitney U-test for non-normally distributed data. Normality was tested with the Kolmogorov-Smirnov test. Subgroup analysis between normal subjects, myocarditis patients with impaired EF, and myocarditis patients with preserved EF was performed with a one-way analysis of variance with Bonferroni's correction for normally distributed data, and the Kruskal-Wallis test with a Mann-Whitney U test for ordinary data or non-normally distributed data. Univariate and backward multivariate Cox proportional hazards models were used to assess independent associations with MACE. After setting the cut-off value using receiver-operating characteristics (ROC) curve analysis, Kaplan-Meier curves were calculated to visualize and compare (log-rank test) patients' MACE-free survival curves. Variables that differed significantly between groups, with or without incomplete LV functional recovery on univariate analysis, were analyzed using backward logistic regression analysis to identify independent predictors of incomplete LV functional recovery. ROC analysis was performed to assess the ability of selected variables to predict incomplete LV functional recovery. After setting the cut-off value, the sensitivity and specificity values for incomplete LV recovery were calculated. Finally, intra- and inter-observer reproducibility was calculated using the intra-class correlation coefficient (ICC), where an ICC value < 0.4 represented poor reproducibility, ICC scores between 0.4 and 0.75 indicated fair-to-good reproducibility, and ICC scores > 0.75 indicated excellent reproducibility. A p value < 0.05 was taken to indicate statistical significance.

RESULTS

Study Population

Table 1 summarizes the characteristics of the study cohort. The mean age of the patients was 41.5 ± 17.5 years and 15 (40.5%) patients were female. The most common symptoms were dyspnea and chest pain, followed by respiratory symptoms, and presyncope or syncope. When patients were stratified by the initial clinical manifestation of the disease, 17 patients (45.9%) had infarct-like onsets. Also, 9 patients (24.3%) had arrhythmia such as atrioventricular block (n = 4, 10.8%), left or right bundle branch block (n = 4, 10.8%), and ventricular tachycardia (n = 1, 2.7%). The majority of patients had an abnormal ECG upon admission (n = 31, 83.8%), with ST elevation as the most common finding (n = 15, 40.5%), followed by ST depression (n = 9, 24.3%). EMB was performed in seven patients (18.9%), of whom six were diagnosed with myocarditis using the Dallas criteria. A single patient had a sample insufficient for diagnosis. Beta blockers were used in 20 patients (54.1%).

CMR Findings

Cardiovascular magnetic resonance was performed within 11.6 ± 8.5 days (range: 0–31 days) of symptom onset in the myocarditis patients. The mean LVEF value was 45.8%, and the mean LVEDVI was 81.4 mL/m2 (Table 2). LGE, which was present in 23 of 37 patients (62.2%), was typically located in mid-wall (6/23, 26.1%) or subepicardial areas (17/23, 73.9%) of the LV wall. There were significant differences between patient and control groups in terms of LVESVI, LVMI, and LVEF. LVEDVI tended to be higher in patients with acute myocarditis. Furthermore, all myocardial strain parameters, including EccSAX, ErrSAX, EllLV, and ErrLax, were significantly lower in patients with myocarditis. Three subgroups showed no significant differences in age (p = 0.051), sex (p = 0.824), and body mass index (p = 0.463) (Table 3). All myocardial strain parameters of myocarditis patients with impaired LV function were significantly reduced compared to normal subjects. Also, EccSAX (−10.36 ± 3.76 vs. −14.76 ± 2.03, p = 0.001), EllLV (−11.48 ± 4.53 vs. −17.52 ± 4.45, p = 0.008), and ErrLax (19.60 ± 8.29 vs. 36.25 ± 15.15, p = 0.001) showed significant differences between patients with preserved EF and normal subjects. However, there were no significant differences in all strain parameters between myocarditis patients with impaired EF and patients with preserved EF. There was excellent intra-observer reproducibility between the first and second evaluations for all strain parameters (ICC = 0.87–0.98) (Table 4). There was also excellent inter-observer reproducibility between two observers for all strain parameters (ICC = 0.90–0.94). There was excellent intra-observer reproducibility (ICC = 0.84–0.97) for LVEDVI, LVESVI, LVMI, and LVEF measurements. Fair-to-good intra-observer reproducibility (ICC = 0.68) was determined for RVEF measurements.

Clinical Outcomes: MACE

All 37 patients were available for clinical follow-up for at least one year. During an average follow-up of 41 ± 34 months (range: 0–112 months), 11 of 37 patients (29.7%) suffered a MACE, including cardiac death (n = 2), heart transplantation (n = 1), cardiac pacemaker (n = 1), rehospitalization due to cardiac events (n = 4), or embolic stroke (n = 3). All cardiac deaths occurred within 1 month of CMR acquisition.
Table 5 displays the results of the univariate Cox regression analysis used to evaluate the predictors of MACE. The analysis revealed that LVMI, LVEF, the presence of LGE, and EccSAX, ErrSAX, EllLV, and ErrLax, values were significant unadjusted predictors of MACE. Multivariable Cox proportional hazard regression analysis, which included LVMI, LVEF, the presence of LGE and EccSAX, ErrSAX, EllLV, and ErrLax values, indicated that the presence of LGE (hazard ratio, 42.88; 95% confidence interval [CI]: 2.15–855.0, p = 0.014) and ErrLax (hazard ratio, 0.77 per 1%; 95% CI: 0.64–0.92, p = 0.004) were significant predictors of MACE.
Receiver-operating characteristic curves for ErrLax to obtain optimal cut-off values for predicting MACE during follow-up showed an area under the curve (AUC) of 0.82 (95% CI: 0.657–0.925). The cut-off value with the best combination of sensitivity and specificity for ErrLax was ≤ 9.48% (sensitivity, 63.6%; specificity, 92.3%) (Fig. 2). Kaplan-Meier survival curves for MACE are displayed in Figure 3. Kaplan-Meier analysis demonstrated that the worst outcomes occurred in patients with LGE and an ErrLax value ≤ 9.48%. Only 1 of 14 patients without LGE (7.1%) experienced MACE, whereas 10 of 23 patients with LGE (43.5%) experienced MACE. Figure 3C shows that outcomes in patients with LGE and an ErrLax value ≤ 9.48% were significantly worse than in patients with LGE and an ErrLax > 9.48%. All patients with LGE and an ErrLax value ≤ 9.48% experienced MACE.

Clinical Outcomes: Functional Improvement

A total of 31 of 37 patients (83.8%) underwent follow-up echocardiography after 1 year. Six patients were excluded because of death during the follow-up period (2/31, 6.5%) or absence of follow-up echocardiography (4/31, 12.9%). Of the 31 patients, 71% (22/31) had normal LVEF on follow-up echocardiography, and 16% (5/31) had normal LVEF on initial echocardiography. Table 6 lists the results of univariate analysis by logistic regression. A multivariable backward stepwise regression analysis, that included LVEDVI, LVESVI, LVEF, EccSAX, ErrSAX, EllLV, and ErrLax values, demonstrated that ErrLax was the only significant predictor of incomplete LV functional recovery (hazard ratio, 0.54 per 1%; 95% CI: 0.29–0.976; p = 0.042). ROC curves for ErrLax to obtain optimal cut-off values for the prediction of incomplete LV functional recovery during follow-up showed an AUC value of 0.96 (95% CI: 0.82–1.0) (Fig. 4). The cut-off value with the best combination of sensitivity and specificity for ErrLax was 14.9% (sensitivity, 88.9%; specificity, 95.5%).

DISCUSSION

This retrospective study presented the following results: 1) all myocardial strain parameters were significantly impaired in patients with acute myocarditis, 2) even patients with a preserved EF showed significantly reduced EccSAX, EllLV, and ErrLax, 3) ErrLax measured on CMR independently predicted MACE or normalized LVEF values in patients with acute myocarditis, 4) all patients with LGE and low ErrLax values experienced MACE.
In contrast to previous studies (521), we included CMR-derived myocardial strain as a possible predictor of MACE or incomplete LV functional recovery in acute myocarditis. Few previous studies have evaluated LV strain in echocardiography of patients with acute myocarditis, or its prognostic values (10). Hsiao et al. (10) reported that longitudinal and circumferential strain measured with echocardiography were significant predictors of major clinical events in 45 acute myocarditis patients. However, their study employed a relatively short follow-up period (mean = 19.8 months), and did not adjust for potential confounding factors through the use of multivariate analysis. Furthermore, echocardiography is inherently limited in patients with poor echogenic windows, and echocardiographic strain parameters may depend on insonation angle (22).
Cardiovascular magnetic resonance-derived feature tracking using steady-statefree precession CMR images is analogous to echocardiographic speckle tracking, but uses a higher spatial resolution and reproducible wall motion tracking (23). One recent study reported that CMR-derived myocardial strain measured with the feature tracking method can predict preserved residual EF in ST elevation myocardial infarction (22). CMR-derived myocardial strain can predict acute myocarditis with high sensitivity and specificity, and significantly reduced cardiac strain is shown even in patients with a preserved EF (91424). However, there are no prior studies on the predictive value of CMR-derived myocardial strain measurements in acute myocarditis patients.
In this study, all strain parameters, including EccSAX, ErrSAX, EllLV, and ErrLax values, were characterized by excellent intra- and inter-observer reproducibility. This result agrees with those of previous studies of CMR feature tracking methods in which considerable intra-observer reproducibility in global myocardial strain measurements was demonstrated (25). In the present study, intra-observer reproducibility was lower for EccSAX than for ErrSAX and EllLV in contrast to previous reports in which EccSAX was the most reproducible strain parameter (2526). This discrepancy may be due to differences in the software used to obtain myocardial strain measurements. Schuster et al. (27), compared the reproducibility of CMR feature-tracking softwares, and found that Circle had better reproducibility for ErrSAX than TomTec (Diogenes or 2D Cardiac Performance Analysis-MR, TomTec GmbH, Unterschleissheim, Germany). In that study, ErrSAX was more reproducible than EccSAX using Circle, which is similar to the result of the present study. Therefore, further studies are required to assess intra- and inter-observer reproducibility of EllLV and ErrLax with respect to the type of feature tracking software used.
Myocardial LGE is a marker of irreversible myocardial injury, e.g., necrosis and fibrosis (16). The presence of LGE is reportedly an independent predictor of a poor outcome, defined as heart transplantation, the requirement for extracorporeal membrane oxygenation or a ventricular assist device, and/or death (521), is in agreement with the present results. Moreover, a recent study of the long-term outcome of patients after acute myocarditis found that NYHA functional class > II and larger LGE mass were independent predictors for the occurrence of long-term MACE (24). LGE was detected in 62.2% of patients in this study, which is a relatively high proportion compared with the 53.2% detected in a previous report (53.2%) (5). This discrepancy may be due to differences in the interval between clinical onset of the disease and CMR examination (mean duration = 11.6 days vs. < 5 days), as well as the characteristics of the study populations. CMR studies conducted during the first day of myocarditis may be less sensitive than those conducted after 7 days because of the focal nature of the early stages of the disease (16). The prominence of LGE may vary accordingly.
The present analysis of the subgroup of patients who underwent follow-up echocardiography revealed that ErrLax values ≤ 14.9% independently predicted incomplete functional recovery (p = 0.042). Although a similar result was obtained previously for myocardial infarction (22), this study assessed, for the first time, the relationship between ErrLax values and myocardial strain. This relationship was based on an analysis of cine images using a feature tracking method during incomplete LV functional recovery in myocarditis. Unexpectedly, LGE did not appear to play a prominent role in this subgroup, contrary to data from a previous myocarditis study (4). This discrepancy may have been due to death during follow-up or absence of follow-up echocardiography in a subgroup of patients. Either of these might introduce a selection bias that could affect the reliability of the data and result in an underestimation of the role of LGE.
This study had several limitations. Its retrospective design and relatively small sample size could be improved in the future by the use of prospective designs and larger cohorts. It included clinically validated suspected acute myocarditis patients only. EMB was not used as a reference standard because of its limited sensitivity (28), and it is not routinely performed in clinical practice. Several previous studies (102930) also relied on a combination of clinical, laboratory, ECG and angiographic findings to identify myocarditis. Furthermore, we could not use Lake Louise Criteria for diagnosis of acute myocarditis, because a T2-weighted sequence or an early gadolinium enhancement sequence was not performed in most cases. Therefore, we included patients with clinically suspected myocarditis according to a combination of clinical, laboratory, ECG and angiographic findings. CMR scanners with different field strengths (i.e., 1.5T and 3T scanners) were used in the present study, which may have affected the imaging analyses. However, previous studies indicated no significant differences in global strain parameters, volumes or EF were found with different field strengths (25).
In conclusion, CMR-derived LV radial strain (ErrLax) values can predict MACE or normalized LVEF in patients with acute myocarditis. The presence of scars, indicated by LGE, is also a good independent predictor of MACE. These results indicate that large, longitudinal follow-up studies are required to further establish LGE and CMR-derived myocardial strain as independent predictors of MACE in acute myocarditis.

Acknowledgments

We acknowledge the assistance of the Pusan National Hospital clinical trial center biostatistics office with the statistical analysis.

References

1. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012; 379:738–747. PMID: 22185868.
crossref
2. Kasper EK, Agema WR, Hutchins GM, Deckers JW, Hare JM, Baughman KL. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol. 1994; 23:586–590. PMID: 8113538.
crossref
3. Drory Y, Turetz Y, Hiss Y, Lev B, Fisman EZ, Pines A, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol. 1991; 68:1388–1392. PMID: 1951130.
4. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006; 114:1581–1590. PMID: 17015795.
crossref
5. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012; 59:1604–1615. PMID: 22365425.
6. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008; 118:639–648. PMID: 18645053.
crossref
7. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007; 50:1914–1931. PMID: 17980265.
crossref
8. Ng AC, Delgado V, Bertini M, Antoni ML, van Bommel RJ, van Rijnsoever EP, et al. Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: a two-dimensional speckle tracking analysis. Eur Heart J. 2011; 32:1542–1550. PMID: 21447510.
crossref
9. Augustine D, Lewandowski AJ, Lazdam M, Rai A, Francis J, Myerson S, et al. Global and regional left ventricular myocardial deformation measures by magnetic resonance feature tracking in healthy volunteers: comparison with tagging and relevance of gender. J Cardiovasc Magn Reson. 2013; 15:8. PMID: 23331550.
crossref
10. Hsiao JF, Koshino Y, Bonnichsen CR, Yu Y, Miller FA Jr, Pellikka PA, et al. Speckle tracking echocardiography in acute myocarditis. Int J Cardiovasc Imaging. 2013; 29:275–284. PMID: 22736428.
crossref
11. Morton G, Schuster A, Jogiya R, Kutty S, Beerbaum P, Nagel E. Inter-study reproducibility of cardiovascular magnetic resonance myocardial feature tracking. J Cardiovasc Magn Reson. 2012; 14:43. PMID: 22721175.
crossref
12. Ibrahim el-SH. Myocardial tagging by cardiovascular magnetic resonance: evolution of techniques--pulse sequences, analysis algorithms, and applications. J Cardiovasc Magn Reson. 2011; 13:36. PMID: 21798021.
crossref
13. Hor KN, Gottliebson WM, Carson C, Wash E, Cnota J, Fleck R, et al. Comparison of magnetic resonance feature tracking for strain calculation with harmonic phase imaging analysis. JACC Cardiovasc Imaging. 2010; 3:144–151. PMID: 20159640.
crossref
14. Baeßler B, Schaarschmidt F, Dick A, Michels G, Maintz D. Diagnostic implications of magnetic resonance feature tracking derived myocardial strain parameters in acute myocarditis. Eur J Radiol. 2016; 85:218–227. PMID: 26724669.
crossref
15. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006; 113:876–890. PMID: 16476862.
16. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009; 53:1475–1487. PMID: 19389557.
crossref
17. Schultz JC, Hilliard AA, Cooper LT Jr, Rihal CS. Diagnosis and treatment of viral myocarditis. Mayo Clin Proc. 2009; 84:1001–1009. PMID: 19880690.
crossref
18. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004; 109:1250–1258. PMID: 14993139.
crossref
19. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013; 34:2636–2648. 2648a–2648d. PMID: 23824828.
crossref
20. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18:1440–1463. PMID: 16376782.
crossref
21. Sachdeva S, Song X, Dham N, Heath DM, DeBiasi RL. Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis. Am J Cardiol. 2015; 115:499–504. PMID: 25554534.
crossref
22. Buss SJ, Krautz B, Hofmann N, Sander Y, Rust L, Giusca S, et al. Prediction of functional recovery by cardiac magnetic resonance feature tracking imaging in first time ST-elevation myocardial infarction. Comparison to infarct size and transmurality by late gadolinium enhancement. Int J Cardiol. 2015; 183:162–117. PMID: 25675901.
crossref
23. Onishi T, Saha SK, Ludwig DR, Onishi T, Marek JJ, Cavalcante JL, et al. Feature tracking measurement of dyssynchrony from cardiovascular magnetic resonance cine acquisitions: comparison with echocardiographic speckle tracking. J Cardiovasc Magn Reson. 2013; 15:95. PMID: 24134158.
crossref
24. André F, Stock FT, Riffel J, Giannitsis E, Steen H, Scharhag J, et al. Incremental value of cardiac deformation analysis in acute myocarditis: a cardiovascular magnetic resonance imaging study. Int J Cardiovasc Imaging. 2016; 32:1093–1101. PMID: 27100527.
crossref
25. Schuster A, Morton G, Hussain ST, Jogiya R, Kutty S, Asrress KN, et al. The intra-observer reproducibility of cardiovascular magnetic resonance myocardial feature tracking strain assessment is independent of field strength. Eur J Radiol. 2013; 82:296–301. PMID: 23246014.
crossref
26. Schuster A, Paul M, Bettencourt N, Morton G, Chiribiri A, Ishida M, et al. Cardiovascular magnetic resonance myocardial feature tracking for quantitative viability assessment in ischemic cardiomyopathy. Int J Cardiol. 2013; 166:413–420. PMID: 22130224.
crossref
27. Schuster A, Stahnke VC, Unterberg-Buchwald C, Kowallick JT, Lamata P, Steinmetz M, et al. Cardiovascular magnetic resonance feature-tracking assessment of myocardial mechanics: Intervendor agreement and considerations regarding reproducibility. Clin Radiol. 2015; 70:989–998. PMID: 26139384.
crossref
28. Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol. 1989; 14:915–920. PMID: 2794278.
crossref
29. Abdel-Aty H, Boyé P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005; 45:1815–1822. PMID: 15936612.
crossref
30. Laissy JP, Messin B, Varenne O, Iung B, Karila-Cohen D, Schouman-Claeys E, et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest. 2002; 122:1638–1648. PMID: 12426265.
Fig. 1

Myocardial strain measurement by feature tracking method in 43-year-old female patient with acute myocarditis.

After endocardial and epicardial borders of LV were traced semi-automatically, software (CVI42) automatically tracked endocardial and epicardial borders across frames during cardiac cycle. EccSAX and ErrSAX measurements (A) were obtained using mid-ventricular level short-axis cine views. EllLV and ErrLax measurements (B) were obtained from 2-chamber long-axis view. EccSAX = LV circumferential strain measured from short-axis cine views, EllLV = LV longitudinal strain measured from long-axis cine views, ErrLax = LV radial strain measured from long-axis cine views, ErrSAX = LV radial strain measured from short-axis cine views, LV = left ventricular
kjr-18-643-g001
Fig. 2

Receiver operating characteristic curve for prediction of MACE.

MACE was defined in terms of cardiac death, heart transplantation, implantable cardioverter defibrillator or pacemaker, rehospitalization following cardiac event, or embolic stroke. AUC = area under the curve, ErrLax = LV radial strain measured from long-axis cine views, LV = left ventricle, MACE = major adverse cardiovascular events
kjr-18-643-g002
Fig. 3

MACE according to ErrLax or presence of LGE.

A. Survivial in patients with ErrLax ≤ 9.48% vs. those with ErrLax > 9.48%. Note that only one patient without LGE experienced MACE dring follow-up. B. Survivial in patients with LGE vs. those without LGE. C. Survivial in patients with ErrLax ≤ 9.48% and presence of LGE vs. those with ErrLax ≤ 9.48% and presence of LGE vs. those without LGE. Patients with LGE and decreased ErrLax (≤ 9.48%) had worse outcome, compared to patients with LGE only. CMR = cardiovascular magnetic resonance, ErrLax = LV radial strain measured from long-axis cine views, LGE = late gadolinium enhancement, LV = left ventricle, MACE = major adverse cardiovascular events
kjr-18-643-g003
Fig. 4

Receiver operating characteristic curve for prediction of incomplete left ventricular functional recovery.

AUC = area under the curve, ErrLax = LV radial strain measured from long-axis cine views, LV = left ventricle
kjr-18-643-g004
Table 1

Baseline Characteristics of Patients

kjr-18-643-i001
Patients with Follow-Up (n = 37)
Age, years 41.5 ± 17.5
Female 15 (40.5)
BMI, kg/m2 22.5 ± 2.8
Past history
 Hypertension 3 (8.1)
 Hypercholesterolemia 0 (0)
 Diabetes 2 (5.4)
 Smoking 7 (18.9)
Duration between symptom onset and CMR examination, days 11.6 ± 8.5
Clinical presentation
 Respiratory symptoms 16 (43.2)
 Chest pain 22 (59.5)
 Palpitation 2 (5.4)
 Dyspnea 22 (59.5)
 Presyncope or syncope 12 (32.4)
 Fever 10 (27.0)
ECG alteration 31 (83.8)
 ST elevation 15 (40.5)
 ST depression 9 (24.3)
 Negative T 7 (18.9)
 Pathologic Q 4 (10.8)
 AV block 4 (10.8)
 LBBB or RBBB 4 (10.8)
 Ventricular tarchycardia 1 (2.7)
Initial NYHA functional class
 I/II 15 (40.5)
 III/IV 22 (59.5)
Initial blood testing
 Troponin I, ng/mL 9.5 ± 13.0
 BNP, pg/mL 1168.7 ± 1229.3
 CK-MB, ug/L 39.0 ± 36.5
Patients who underwent endomyocardial biopsy 7 (18.9)
Beta-blocker medication 20 (54.1)
MACE 11 (29.7)

Data are provided as n (%) or mean ± SD. AV = atrioventricular, BMI = body mass index, BNP = brain natriuretic peptide, CK-MB = creatine kinase MB, CMR = cardiovascular magnetic resonance, ECG = electrocardiography, LBBB = left bundle branch block, MACE = major adverse cardiovascular events, NYHA = New York Heart Association, RBBB = right bundle branch block

Table 2

CMR Findings of Patients with Acute Myocarditis and Normal Subjects

kjr-18-643-i002
Myocarditis Patients (n = 37) Normal Subjects (n = 10) P
Age, years 41.5 ± 17.5 36.2 ± 10.0 0.274
Female 15 (40.5) 5 (50.0) 0.723
BMI, kg/m2 22.5 ± 2.8 22.0 ± 3.2 0.640
CMR imaging parameter
 LVEDVI, mL/m2 81.4 ± 39.4 67.2 ± 10.1 0.310
 LVESVI, mL/m2 48.9 ± 41.3 26.6 ± 5.3 0.003
 LVMI, g/m2 67.7 ± 23.5 46.4 ± 11.2 0.008
 RVEF, % 50.8 ± 14.2 59.1 ± 5.3 0.075
 LVEF, % 45.8 ± 17.1 60.7 ± 3.0 0.001
 Presence of LGE 23 (62.2) NA NA
 EccSAX, % −9.53 ± 4.87 −14.76 ± 2.03 < 0.001
 ErrSAX, % 14.81 ± 7.77 23.46 ± 5.20 0.002
 EllLV, % −10.58 ± 4.76 −17.52 ± 4.45 < 0.001
 ErrLax, % 19.13 ± 8.88 36.25 ± 15.15 < 0.001

Values are n (%) or means ± SD. BMI = body mass index, CMR = cardiovascular magnetic resonance, EccSAX = LV circumferential strain measured from short-axis cine views, EllLV = LV longitudinal strain measured from long-axis cine views, ErrLax = LV radial strain measured from long-axis cine views, ErrSAX = LV radial strain measured from short-axis cine views, LGE = late gadolinium enhancement, LV = left ventricle, LVEDVI = left ventricular end-diastolic volume index, LVEF = left ventricular ejection fraction, LVESVI = left ventricular end-systolic volume index, LVMI = left ventricular mass index, NA = not applicable, RVEF = right ventricular ejection fraction

Table 3

Comparison of Myocardial Stain Parameters between Myocarditis Patients without and with Preserved EF and Normal Subjects

kjr-18-643-i003
Patients with Impaired EF (n =21) Patients with Preserved EF (n =16) Normal Subjects (n = 10) P
Age, years 36.1 ± 17.8 48.5 ± 14.8 36.2 ± 10.0 0.051
Female 9 (42.9) 6 (37.5) 5 (50.0) 0.824
BMI, kg/m2 22.0 ± 3.0 23.1 ± 2.5 22.0 ± 3.2 0.463
Strain parameters
 EccSAX, % −8.90 ± 5.57 −10.36 ± 3.76* −14.76 ± 2.03*† 0.002
 ErrSAX, % 13.50 ± 7.40 16.54 ± 8.12 23.46 ± 5.20 0.004
 EllLV, % −9.89 ± 4.92 −11.48 ± 4.53* −17.52 ± 4.45*† < 0.001
 ErrLax, % 18.78 ± 9.50 19.60 ± 8.29* 36.25 ± 15.15*† < 0.001

Values are n (%) or means ± SD. *Significantly different between myocarditis patients with preserved EF and normal subjects, Significantly different between myocarditis patients with impaired EF and normal subjects. BMI = body mass index, EccSAX = LV circumferential strain measured from short-axis cine views, EF = ejection fraction, EllLV = LV longitudinal strain measured from long-axis cine views, ErrLax = LV radial strain measured from long-axis cine views, ErrSAX = LV radial strain measured from short-axis cine views, LV = left ventricle

Table 4

Intra-Observer and Inter-Observer Reproducibility According to Intra-Class Correlation for Strain Quantification on CMR

kjr-18-643-i004
Intra-Observer ICC (95% CI) Inter-Observer ICC (95% CI)
EccSAX 0.92 (0.80–0.97) 0.93 (0.83–0.97)
ErrSAX 0.98 (0.96–0.99) 0.92 (0.82–0.97)
EllLV 0.97 (0.92–0.99) 0.94 (0.86–0.98)
ErrLax 0.87 (0.71–0.95) 0.90 (0.76–0.96)

CI = confidence interval, CMR = cardiovascular magnetic resonance, EccSAX = LV circumferential strain measured from short-axis cine views, EllLV = LV longitudinal strain measured from long-axis cine views, ErrLax = LV radial strain measured from long-axis cine views, ErrSAX = LV radial strain measured from short-axis cine views, ICC = intra-class correlation coefficient, LV = left ventricle

Table 5

Univariate Cox Regression Analysis: MACE

kjr-18-643-i005
MACE (n = 11) No MACE (n = 25) HR (95% CI) P
Age, years 45.0 ± 15.0 40.0 ± 18.5 1.01 (0.97–1.05) 0.624
Female 5 (45.5) 10 (40.0) 1.32 (0.39–4.41) 0.655
BMI, kg/m2 22.5 ± 1.1 22.5 ± 3.3 1.02 (0.82–1.27) 0.874
Past history
 Hypertension 0 (0) 3 (12.0) 0.04 (0.0–262.62) 0.477
 Hypercholesterolemia 0 (0) 0 (0) NA NA
 Diabetes 1 (9.9) 1 (4.0) 3.10 (0.38–25.41) 0.293
 Smoking 3 (27.3) 4 (16.0) 1.43 (0.52–3.93) 0.490
ECG alteration
 ST elevation 2 (18.2) 13 (52.0) 0.29 (0.06–1.34) 0.112
 ST depression 1 (9.9) 8 (32.0) 0.33 (0.04–2.60) 0.290
 Negative T 3 (27.3) 4 (16.0) 1.32 (0.33–5.25) 0.689
 Pathologic Q 1 (9.9) 3 (12.0) 0.82 (0.10–6.41) 0.848
 AV block 2 (18.2) 2 (8.0) 0.61 (0.13–2.88) 0.530
 LBBB or RBBB 1 (9.1) 3 (12.0) 1.22 (0.15–9.79) 0.852
 Ventricular tachycardia 0 (0) 1 (4.0) 0.47 (0–458654.76) 0.710
Initial NYHA functional class
 III/IV 8 (72.7) 14 (56.0) 2.14 (0.57–8.12) 0.263
Initial blood testing
 Troponin I, ng/mL 10.3 ± 12.2 17.9 ± 24.9 0.98 (0.94–1.02) 0.289
 BNP, pg/mL 1125.5 ± 91.02 748.4 ± 761.5 1.00 (1.00–1.00) 0.126
 CK-MB, ug/L 17.8 ± 27.3 57.7 ± 60.1 0.98 (0.96–1.00) 0.103
 Beta-blocker medication 6 (54.5) 14 (56.0) 0.89 (0.27–2.90) 0.836
CMR imaging parameter
 LVEDVI, mL/m2 102.7 ± 59.4 72.4 ± 23.3 1.01 (1.00–1.02) 0.119
 LVESVI, mL/m2 75.7 ± 62.2 37.6 ± 21.4 1.01 (1.00–1.02) 0.073
 LVMI, g/m2 81.4 ± 33.3 61.9 ± 15.4 1.02 (1.00–1.05) 0.039
 RVEF, % 42.9 ± 17.1 54.1 ± 11.6 0.97 (0.93–1.00) 0.068
 LVEF, % 33.4 ± 17.8 61.2 ± 10.0 0.96 (0.93–0.99) 0.007
 Presence of LGE 10 (90.9) 13 (50.0) 9.93 (1.25–79.0) 0.030
 EccSAX, % -6.2 ± 6.0 -10.9 ± 3.6 1.20 (1.07–1.35) 0.003
 ErrSAX, % 9.5 ± 6.2 17.0 ± 7.4 0.87 (0.79–0.96) 0.005
 EllLV, % -7.0 ± 3.8 -12.2 ± 4.2 1.33 (1.11–1.61) 0.003
 ErrLax, % 12.2 ± 8.0 22.1 ± 7.6 0.87 (0.80–0.95) 0.002

Values are n (%) or mean ± SD. AV = atrioventricular, BMI = body mass index, BNP = brain natriuretic peptide, CI = confidence interval, CK-MB = creatine kinase MB, CMR = cardiovascular magnetic resonance, EccSAX = LV circumferential strain measured from short-axis cine views, ECG = electrocardiography, EllLV = LV longitudinal strain measured from long-axis cine views, ErrLax = LV radial strain measured from long-axis cine views, ErrSAX = LV radial strain measured from short-axis cine views, HR = hazard ratio, LBBB = left bundle branch block, LGE = late gadolinium enhancement, LV = left ventricle, LVEDVI = LV end-diastolic volume index, LVEF = LV ejection fraction, LVESVI = LV end-systolic volume index, LVMI = LV mass index, MACE = major adverse cardiovascular events, NA = not applicable, NYHA = New York Heart Association, RBBB = right bundle branch block, RVEF = right ventricular ejection fraction

Table 6

Univariate Analysis: Incomplete Left Ventricular Functional Recovery

kjr-18-643-i006
Total (n = 31) Incomplete LV Functional Recovery (n = 9) Complete LV Functional Recovery (n = 22) Odds Ratio (95% CI) P
Age, years 42.4 ± 17.1 51.8 ± 14.9 38.5 ± 16.7 1.06 (1.0–1.12) 0.063
Female 12 (38.7) 4 (30.8) 9 (69.2) 1.16 (0.24–5.53) 0.856
BMI, kg/m2 22.4 ± 2.8 22.8 ± 2.8 22.2 ± 2.9 1.08 (0.81–1.43) 0.617
Past history
 Hypertension 3 (9.7) 2 (66.7) 1 (33.3) 6.0 (0.47–76.71) 0.168
 Diabetes 2 (6.5) 2 (100.0) 0 (0) NA 0.999
 Smoking habit 5 (16.1) 1 (1.1) 4 (18.2) 0.56 (0.05–5.86) 0.630
ECG alteration
 ST elevation 12 (38.7) 1 (8.3) 11 (91.7) 0.13 (0.13–1.18) 0.069
 ST depression 9 (29.0) 3 (33.3) 6 (66.7) 1.33 (0.25–7.11) 0.736
 Negative T 5 (16.1) 1 (20.0) 4 (80.0) 0.56 (0.05–5.86) 0.630
 Pathologic Q 3 (9.7) 0 (0) 3 (100.0) NA 0.999
 AV block 3 (9.7) 1 (11.1) 2 (9.1) 6.0 (0.47–76.7) 0.168
 LBBB or RBBB 4 (1.3) 1 (11.1) 3 (13.6) 7.92 (0.07–8.81) 0.849
 Ventricular tarchycardia 1 (3.2) 0 (0) 1 (4.5) NA NA
Initial NYHA functional class
 III/IV 21 (67.7) 7 (77.8) 14 (63.6) 2.0 (0.33–12.05) 0.449
Initial blood testing
 Troponin I, ng/mL 15.3 (21.9) 79.3 (34.4) 13.6 (14.6) 1.01 (0.98–1.05) 0.515
 BNP, pg/mL 917 (882.9) 1010.6 (1068.4) 876 (825.1) 1.00 (1.00–1.00) 0.732
 CK-MB, ug/L 47.2 (53.1) 44 (48.5) 48.5 (46.6) 1.00 (0.98–1.02) 0.834
 Beta-blocker medication 17 (45.2) 4 (44.4) 13 (59.1) 0.55 (0.12–2.65) 0.459
CMR imaging parameter
 LVEDVI, mL/m2 79.2 ± 37.8 112.9 ± 54.6 65.5 ± 14.8 1.08 (1.01–1.45) 0.019
 LVESVI, mL/m2 46.6 ± 40.5 84.7 ± 58.3 31.1 ± 13.2 1.10 (1.0–1.18) 0.011
 LVMI, g/m2 114.0 ± 45.3 79.5 ± 33.7 63.2 ± 19.1 1.03 (0.99–1.06) 0.109
 RVEF, % 91.1 ± 28.2 43.5 ± 18.7 54.7 ± 10.4 0.94 (0.89–1.00) 0.059
 LVEF, % 46.8 ± 16.9 29.1 ± 13.4 54.0 ± 12.4 0.89 (0.82–0.96) 0.003
 Presence of LGE 20 (64.5) 7 (77.8) 13 (59.1) 1.39 (0.27–7.04) 0.698
 EccSAX, % −10.1 ± 4.2 −6.2 ± 4.6 −11.7 ± 2.9 1.47 (1.13–1.91) 0.005
 ErrSAX, % 15.5 ± 7.7 7.4 ± 3.9 18.8 ± 6.3 0.69 (0.54–0.89) 0.004
 EllLV, % −11.2 ± 4.6 −7.3 ± 3.1 −12.8 ± 4.1 1.46 (1.10–1.95) 0.009
 ErrLax, % 20.3 ± 8.8 10.5 ± 5.3 24.2 ± 6.3 0.70 (0.55–0.90) 0.005

Values are n (%) or means ± SD. AV = atrioventricular, BMI = body mass index, BNP = brain natriuretic peptide, CK-MB = creatine kinase MB, CMR = cardiovascular magnetic resonance, EccSAX = LV circumferential strain measured from short-axis cine views, ECG = electrocardiography, EllLV = LV longitudinal strain measured from long-axis cine views, ErrLax = LV radial strain measured from long-axis cine views, ErrSAX = LV radial strain measured from short-axis cine views, LBBB = left bundle branch block, LGE = late gadolinium enhancement, LV = left ventricle, LVEDVI = LV end-diastolic volume index, LVEF = LV ejection fraction, LVESVI = LV end-systolic volume index, LVMI = LV mass index, MACE = major adverse cardiovascular events, NA = not applicable, NYHA = New York Heart Association, RBBB = right bundle branch block, RVEF = right ventricular ejection fraction

TOOLS
Similar articles